Article may be outdated

This article is 10 days old. Some details may have changed since publication.

Targeted Oncology·4 min read·hard

Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers

A
Aman Chauhan, MD
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
✦AI Summary

Dr. Aman Chauhan discusses a new clinical approach for treating neuroendocrine cancers using intralesional injections of the Seneca Valley virus combined with immunotherapy. This method aims to overcome the limitations of previous intravenous delivery attempts that were neutralized by the immune system.

Why it matters

Refining drug delivery methods for oncolytic viruses could significantly improve outcomes for patients with aggressive, hard-to-treat cancers.

✦Dive DeeperCreate a free account to unlock

Aman Chauhan, MD, discusses a first-in-human study of intratumoral Seneca Valley virus (SVV-001) combined with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with neuroendocrine cancer. In this interview from the 2026 North American Neuroendocrine Tumor Society (NANETS) Symposium, he explains why earlier intravenous studies of this oncolytic virus failed to show benefit, and how a change in the route of administration reopened the question.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in